SB17170 (and its active metabolite SB1703) is a small molecule that selectively binds HMGB1 and, in immunocompetent syngeneic models, reduces circulating HMGB1 and tumor-associated MDSCs while enhancing T-cell infiltration and checkpoint blockade responses [247]. This evidence concerns the gene HMGB1 and neoplasm.